A new global survey from Merck Animal Health reveals widespread frustration with canine allergic skin disease, as veterinarians and pet owners report challenges with diagnosis, treatment effectiveness, affordability and long-term compliance.
Rejuvenate Bio has secured $6 million in new funding and launched a strategic R&D collaboration with Merck Animal Health to advance gene therapies targeting chronic and age-related diseases in companion animals.
The acquisition would add TARGAN’s automated hatchery technologies, including high-speed chick sex-sorting and vaccine delivery platforms, further expanding Merck Animal Health’s position in the global poultry sector.
The FDA has approved an expanded label for BRAVECTO QUANTUM, adding 12-month protection against Asian longhorned and Gulf Coast ticks in dogs.
Sign up for free to receive the latest veterinary news, product announcements, and industry developments.